Halozyme Therapeutics Inc (HALO)

[Fred Kadiddlehopper]

It sounds like they know that PEGpH20 is going to succeed.

-------------------------------------------------------------------------------

James William Birchenough, Wells Fargo Securities, LLC, Research Division - MD and Senior Biotechnology Analyst [5]

--------------------------------------------------------------------------------

And then an important question we get is just what Halozyme might look like under different scenarios around HALO-301. And in one scenario, I think you've discussed you could be an ENHANZE-only company if the HALO-301 study doesn't go the way you think it'll go. Is that still the thought, and just trying to reconcile that with perhaps more focus on R&D recently.

--------------------------------------------------------------------------------

Helen I. Torley, Halozyme Therapeutics, Inc. - President, CEO & Director [6]

--------------------------------------------------------------------------------

We believe we've developed PEGPH20 in pancreas cancer that is significantly derisked it versus other pancreas cancer programs. And we are planning for success, and that is obviously why we are continuing to evaluate for future new indications to develop for PEGPH20 and brought in Alison. In the event we are surprised and PEGPH20 is not successful and we do not see a path forward for PEGPH20, we have said the most likely scenario is we would become an ENHANZE-only company. But we are planning for success.

--------------------------------------------------------------------------------